Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 8Fallopian Tube Neoplasms 5Endometrial Neoplasms 5Uterine Cervical Neoplasms 4Melanoma 3Carcinoma, Hepatocellular 3Stomach Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Wilms Tumor 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Pelvic Neoplasms 1Osteosarcoma 1Neuroblastoma 1

Interventions

Specimen Handling 2Nivolumab 2trifluridine tipiracil drug combination 1strattice 1entinostat 1X-Rays 1Sunitinib 1Phantoms, Imaging 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Fluorouracil 1Fentanyl 1CTLA-4 Antigen 1Bone Density 1Bevacizumab 1Absorptiometry, Photon 1Abdominoplasty 14-hydroxy-N-desmethyltamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Desmoid Tumors × X-Rays × Gynecologic × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡